Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increases costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human capital and other costs Novavax will incur to exit the manufacturing facility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that
'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... "Organic Electronics Market by Material, by Application, Geography ... report to their offering. Organic electronics, ... a branch of material science which deals with small ... as organic because small molecules and polymers are carbon ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
(Date:10/20/2014)... Oct. 20, 2014  GenVec, Inc. (NASDAQ: GNVC ... , Ph.D., from its board of directors effective on October ... 2003, and served as its chairman from June 2006 to ... Nominating and Corporate Governance and Audit Committees of the board.  ... a decade of dedicated service to GenVec, and its stockholders," ...
(Date:10/20/2014)... Tigard, OR (PRWEB) October 20, 2014 ... to participate in an investigational study of donor stem ... nationally in stem cell therapy and has performed clinical ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Up Online Simplifies the Donor Designation Process and Saves ... donation,groups today formally unveiled a Web portal that will ... rather than waiting until their driver,s,license or photo ID ... license,center in person. The Web portal, http://www.donatelife-pa.org, ...
... The Center for Molecular,Medicine (CMM) today said it ... nursing mothers for codeine risks cited in a Friday ... Late Friday, the FDA issued an advisory noting new ... nursing infants whose mothers are,taking codeine and are also ...
... Early Detection ... Hypertension in the UK, NEW YORK and MILTON KEYNES, ... INCR), and Omron Healthcare (UK),Ltd., a wholly owned subsidiary of ... hypertension diagnostics and,therapies in the professional and pharmacy healthcare markets. ...
Cached Biology Technology:Web Portal Makes Organ Donation Easy 2Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers 2InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 2InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 3InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 4
(Date:10/16/2014)... SHELTON, Conn. , October 16, 2014 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present its leading edge technologies including Wocket™, the Smart ... Review® (FiRe) Conferenece. FiRe is a leading global conference ... Hosted by Mark Anderson , founder ...
(Date:10/15/2014)... book ,Models of Life, is a non-traditional biophysics textbook ... The book is a journey of discovery into biological ... life and biological regulation. It is about how our ... communication between the billions of cells in an organism. ... relationships between principles, which can be found on both ...
(Date:10/15/2014)... pneumonia in female mice to an enzyme activated by ... more resistant to respiratory infections than males. Now, an ... to bacterial pneumonia in female mice is linked to ... show that this enzyme is ultimately activated by the ... team, lead by Professor Lester Kobzik at the Harvard ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3New book about life as seen from physics 2
... the regressiveness of pollution taxes can be offset by ... labor tax, that approach may not work, and also ... overall real net wages, according to research by a ... a finance professor and former deputy assistant secretary of ...
... Feb. 22, 2011 Reportlinker.com announces that a ... catalogue: Global Bioinformatics Industry ... This report analyzes the worldwide markets for ... Software, Hardware, and Biocontent. The report provides separate ...
... in the global carbon cycle, helping sequester significant amounts ... so numerous, that they discolor coastal waters and reduce ... ecosystem. Previously known as "red tide," the term "harmful ... note accumulation of algal biomass can sometimes also turn ...
Cached Biology News:Pollution tax rebates little help for low-income workers 2Reportlinker Adds Global Bioinformatics Industry 2Brown tide culprit sequenced: Genome of the first of algal bloom species 2Brown tide culprit sequenced: Genome of the first of algal bloom species 3Brown tide culprit sequenced: Genome of the first of algal bloom species 4
...
... This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (R4276) or ... Material: cap polystyrene (expanded surface, easy ...
... Custom Peptide Services offer a full range ... research needs. Services include: Peptide synthesis, ... Peptide synthesis, purified product (70-95% pure) ... amidation, biotinylation, fluorescein, myristylation, phosphorylation, and rhodamine) ...
... Endogens Bovine IFNγ ELISPOT (enzyme-lined immunospot) ... the single cell level. A spot forms ... bound, is counted (either using a dissection ... compared to the number of cells added ...
Biology Products: